查看文章

Nintedanib is a tyrosine kinase inhibitor recently approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Aim of this study was to evaluate the effectiveness and safety of Nintendanib in the treatment of IPF in the real-life. We conducted a multicenter, retrospective, intention to treat study across 5 hospitals in Greece. Patients that received Nintedanib from 2015 to 2018 were included. Demographic data, medical history, adverse event reports and serial Pulmonary function test results were collected from the patients’ files. 132 patients, with a mean age of 72.5 at the initiation of medication were included in the analysis. Patients were in their majority male (82%). 77 were ex-smockers, 25 current and 30 never smokers. The mean treatment period was 16.5 months, while 35 (27%) patients were treated before with other antifibrotic agent. Mean FVC% was 72.5 and DLCO% 39.6, while 14 (10.6%) patients suffered …